What is the appropriate treatment for gynecomastia?

Treatment of Gynecomastia

Most men with clinically diagnosed gynecomastia require no imaging and should be managed with watchful waiting after addressing underlying causes, with surgical excision (gland removal combined with liposuction) reserved for persistent cases lasting beyond 12-24 months or causing significant distress 1.

Initial Diagnostic Approach

The primary goal is identifying reversible causes and excluding malignancy, not routine imaging. Clinical diagnosis alone is sufficient in most cases 2.

Essential Clinical Assessment

• History: Document onset/duration, medication use (spironolactone, finasteride, anabolic steroids), substance abuse, sexual function, and signs of systemic disease 1
• Physical examination: Palpate for firm, rubbery subareolar glandular tissue (confirms true gynecomastia vs. pseudogynecomastia from fat deposition). Examine genitalia for testicular masses or atrophy 1
• Laboratory workup (when indicated): Total testosterone, estradiol, SHBG, LH, FSH, hCG, AFP, prolactin, TSH, liver/renal function 1, 3
• Testicular ultrasound: Recommended as palpation has low sensitivity for detecting tumors 1

When Imaging is NOT Needed

Mammography and ultrasound are not routinely indicated when physical examination clearly demonstrates gynecomastia or pseudogynecomastia 2. The ACR Appropriateness Criteria explicitly state these modalities are "usually not appropriate" for typical presentations 2.

Treatment Algorithm

1. Physiologic Gynecomastia (Observation)

• Neonatal and pubertal gynecomastia: Resolves spontaneously in >90% within 24 months—no intervention needed 1
• Elderly men: Often physiologic; observe unless symptomatic

2. Secondary Gynecomastia (Address Underlying Cause)

• Discontinue offending medications (spironolactone, antiandrogens, anabolic steroids) 1, 4
• Treat underlying conditions: Hyperthyroidism, liver disease, testicular tumors, hypogonadism 4, 3
• Testosterone replacement: Only for documented hypogonadism (low testosterone with symptoms)—not for eugonadal men 1

3. Pharmacologic Therapy (Limited Role)

The EAA guidelines explicitly recommend AGAINST routine use of SERMs (tamoxifen, raloxifene) or aromatase inhibitors in general practice 1. These may be considered only for:

• Pubertal gynecomastia causing severe distress (anti-estrogen treatment) 5
• Recent-onset painful gynecomastia (<6 months duration) in select cases

Key caveat: Medical therapy is ineffective for long-standing fibrotic gynecomastia (>12 months) 4.

4. Surgical Treatment (Definitive Management)

Surgery is the treatment of choice for persistent gynecomastia that fails to resolve spontaneously or with medical management 1, 5.

Surgical Indications:

• Duration >12-24 months (fibrotic tissue unlikely to regress)
• Significant psychological distress or quality-of-life impairment
• Patient preference after failed conservative management

Optimal Surgical Technique:

Traditional subcutaneous gland excision via periareolar incision combined with liposuction provides the most consistent results with lowest complication rates 5. This approach:

• Addresses both glandular and adipose components
• Minimizes visible scarring
• Applicable to Simon grades I-IIb

For severe cases (Simon grade III) with significant skin redundancy:

• Skin excision techniques (boomerang pattern, J-torsoplasty) may be required 6
• Nipple-areolar complex repositioning or grafting for extreme cases 6

Emerging Techniques:

Recent studies describe endoscopic approaches (single-hole or three-hole) combined with liposuction, showing excellent cosmetic outcomes with minimal scarring and high patient satisfaction (>74% highly satisfied) 7, 8. However, these require specialized training and are best suited for experienced surgeons.

Expected Outcomes:

• Overall surgical efficiency: 100% 7
• Complication rate: 10-26% (mostly minor—seroma, superficial skin necrosis, subcutaneous fluid) 9, 7
• Patient satisfaction: High (>90% satisfied to highly satisfied) 9, 8

Critical Pitfalls to Avoid

1. Do not perform routine imaging on clinically obvious gynecomastia—this leads to unnecessary biopsies and patient anxiety 2
2. Do not prescribe SERMs or aromatase inhibitors routinely—evidence does not support widespread use 1
3. Do not delay testicular ultrasound in adult-onset gynecomastia—palpation misses occult tumors 1
4. Do not offer surgery for recent-onset gynecomastia (<12 months)—allow time for spontaneous resolution 1, 4
5. Always exclude malignancy in unilateral, hard, fixed masses or those with nipple discharge—proceed directly to core needle biopsy if suspicious 1, 3

Special Populations

• Age <25 years with indeterminate mass: Start with ultrasound (not mammography) given extremely low cancer risk 2
• Hypogonadal men: Testosterone replacement may resolve gynecomastia if initiated early 1, 4
• Obese patients: Distinguish true gynecomastia from pseudogynecomastia (fat only)—treatment differs 2